The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.565
Low: 1.475
Prev. Close: 1.65
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Shield Therapeutics Replaces Founder

Wed, 22nd Apr 2020 15:13

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday, Tuesday and Wednesday and not separately reported by Alliance News:

----------

Shield Therapeutics PLC - pharmaceuticals - Tim Watts promoted to chief executive officer from chief financial officer, replacing the company's founder, Carl Sterritt. Shield said Sterritt, who formed the company in 2008, resigned "following discussions with major shareholders and with mutual agreement". Watts has been CFO since August 2018, previously having served in the same role at Oxford BioMedica PLC. Watts also worked at AstraZeneca PLC for 22 years.

----------

Bunzl PLC - distributor - Hires Vin Murria as non-executive director, starting June 1. Was founder & chief executive officer of Advanced Computer Software Group PLC. She is currently a non-executive director at Softcat PLC, DWF Group PLC and finnCap Group PLC.

----------

Mobile Streams PLC - data analytics platform - Peter Tomlinson resigns as director immediately, having been with the company for 20 years. Tomlinson stepped in as chair of Mobile Streams at the start of 2018, handing over to Nigel Burton late last year as the company raised equity following a vote by shareholders against delisting the company from AIM. Mobile Streams said Wednesday that Tomlinson "took over as chairman during a difficult time and supported the transition to a new management team".

----------

Metro Bank PLC - Gene Lockhart and Stuart Bernau step down as non-executive directors from May 18, replaced by Anne Grim, Ian Henderson, and Nicholas Winsor. Grim was chief customer officer for fund manager Fidelity International Ltd, and also worked for lenders Barclays PLC and Wells Fargo & Co. Henderson is CEO of Australian know-your-customer service provider Kyckr. Prior that he was chief operating officer for private banking businesses at Barclays Wealth and CEO of RBS International at Royal Bank of Scotland Group PLC. Winsor was CEO of several HSBC Holdings PLC businesses. Metro Bank noted its board now will consist of eight independent non-executive directors and two executive directors.

----------

Centrica PLC - Carlos Pascual and Steve Pusey will step down as non-executive directors from the annual general meeting on May 22.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Apr 2019 18:11

DIRECTOR DEALINGS: Shield Therapeutics Chair Buys GBP40,000 In Shares

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday Chair James Karis bought 50,000 shares in the company.Karis acquired 46,000 shares at GBP0.815 on Monday, then acquired a at

Read more
3 Apr 2019 10:10

Shield Therapeutics narrows losses as it advances Feraccru to market

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced a decent improvement in revenue in its preliminary results on Wednesday, to £11.9m from £0.6m.

Read more
3 Apr 2019 09:56

Shield Therapeutics Cuts Loss In 2018; Licence Payment Lifts Revenue

LONDON (Alliance News) - Drug maker Shield Therapeutics PLC said Wednesday its 2018 loss narrowed significantly as revenue surged on a licence payment boost amid a year of "transition" a

Read more
14 Mar 2019 15:52

Shield Therapeutics Secures Positive Decision On Feraccru's Patent

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said its Feraccru patent met the requirements of the European Patent Convention, which will continue to provide protection to Feraccru

Read more
4 Mar 2019 11:26

Shield Therapeutics upbeat on latest Feraccru trial results

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the AEGIS-H2H clinical trial on Monday, which compared 'Feraccru' (ferric maltol) - a novel oral iron replacement therapy - to 'Ferinject' (ferric carboxymaltose - FCM), the market-leading intravenously delivered iron replacement therapy.

Read more
29 Jan 2019 11:21

Shield Therapeutics Gets Positive Results From Feraccru Study

LONDON (Alliance News) - Shield Therapeutics PLC on Tuesday reported positive results from a long-term study of its lead treatment for iron deficiency, Ferracru.Shares in the company were a

Read more
29 Jan 2019 10:02

Shield Therapeutics upbeat on results of latest Feraccru study

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of 'Feraccru' on Tuesday.

Read more
24 Jan 2019 14:16

Shield Therapeutics Expects 2018 Revenue Growth On Licence Payments

LONDON (Alliance News) - Shield Therapeutics PLC on Thursday said it expects its revenue to surge in 2018 on the back of licence payments for its Feraccru capsules.The pharmaceutical has in

Read more
24 Jan 2019 10:02

Shield Therapeutics revenues surge following commercialisation deal

(Sharecast News) - Shield Therapeutics saw revenues rocket in the second half of its trading year following a commercialisation agreement with European pharmaceutical specialist Norgine.

Read more
22 Jan 2019 13:35

Shield Therapeutics Appoints Director James Karis As Chair

LONDON (Alliance News) - Shield Therapeutics PLC said Tuesday that it has promoted board member James Karis to be non-executive chair with immediate effect.Karis has served on Shield's

Read more
22 Jan 2019 09:56

Shield Therapeutics promotes Karis to chairman

(Sharecast News) - Commercial stage pharmaceutical outfit Shield Therapeutics elevated James Karis to the role of non-executive chairman on Tuesday.

Read more
13 Dec 2018 11:57

FDA gives target date for Shield's Feraccru application

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics announced on Thursday that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of 'Feraccru', under the terms of the Prescription Drug User Fee Act, would be 27 July 2019.

Read more
5 Dec 2018 13:07

Shield Therapeutics' Feraccru treatment launched in UK

(Sharecast News) - Shield Therapeutics' treatment for iron deficiency in adults, Feraccru, was launched in the UK on Wednesday by specialist pharmaceutical company Norgine.

Read more
5 Dec 2018 11:57

Shield Therapeutics Partner Norgine Launches Feraccru In UK

LONDON (Alliance News) - Shield Therapeutics PLC said Wednesday that Norgine BV has launched the company's treatment for iron deficiency, Ferracru, in the UK.In September 2018, Shield,

Read more
24 Sep 2018 14:30

DIRECTOR DEALINGS: Shield Therapeutics Boss Sterritt Buys More Stock

LONDON (Alliance News) - Shield Therapeutics PLC on Monday said Chief Executive Carl Sterritt bought more shares in the company in a deal on Friday last week.Sterritt pruchased 88,235 at 34

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.